NERV says roluperidone phase III trial is on track; results due next year
NERV is advancing roluperidone for negative symptoms of schizophrenia with a confirmatory phase III trial underway. Results are expected in the second half of next year.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.